Company intelligence / Profile preview

Shanghai Meiyue Biotech Development

Shanghai, China

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Shanghai Meiyue Biotech Development is actively researching small molecule inhibitors targeting complement pathways (notably complement factor B) and kinases (MAPK p38, IRAK4). Its leading assets are at the pre-clinical stage with a focus on autoimmune, hematological, and ocular diseases, with public disclosures of new chemical entities but no reported clinical efficacy or human data yet.[6][7][10]

Therapeutic areas: ImmunologyNephrologyRheumatologyOphthalmologyHematologyDermatologyNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

MY009212L

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Shandong Galaxy Bio-Tech

Beyond the preview

Go deeper on Shanghai Meiyue Biotech Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Meiyue Biotech Development.

Explore the full profile